Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 37

1.

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.

Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G; ADOPT Study Group.

N Engl J Med. 2006 Dec 7;355(23):2427-43. Epub 2006 Dec 4. Erratum in: N Engl J Med. 2007 Mar 29;356(13):1387-8.

2.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
3.

Cost-effectiveness of rosiglitazone combination therapy for the treatment of type 2 diabetes mellitus in the UK.

Beale S, Bagust A, Shearer AT, Martin A, Hulme L.

Pharmacoeconomics. 2006;24 Suppl 1:21-34. Review.

PMID:
16800160
4.

Metformin hydrochloride in the treatment of type 2 diabetes mellitus: a clinical review with a focus on dual therapy.

Setter SM, Iltz JL, Thams J, Campbell RK.

Clin Ther. 2003 Dec;25(12):2991-3026. Review.

PMID:
14749143
5.

Oral antidiabetic agents: current role in type 2 diabetes mellitus.

Krentz AJ, Bailey CJ.

Drugs. 2005;65(3):385-411. Review.

PMID:
15669880
6.

Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus.

Wagstaff AJ, Goa KL.

Drugs. 2002;62(12):1805-37. Review.

PMID:
12149047
7.
8.

[Metformin for type-2 diabetes mellitus. Systematic review and meta-analysis].

Sáenz Calvo A, Fernández Esteban I, Mataix Sanjuán A, Ausejo Segura M, Roqué M, Moher D.

Aten Primaria. 2005 Sep 15;36(4):183-91. Review. Spanish.

9.

What to add in with metformin in type 2 diabetes?

Petrie JR, Adler A, Vella S.

QJM. 2011 Mar;104(3):185-92. doi: 10.1093/qjmed/hcq237. Epub 2010 Dec 13. Review.

10.

Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus.

Bolen S, Feldman L, Vassy J, Wilson L, Yeh HC, Marinopoulos S, Wiley C, Selvin E, Wilson R, Bass EB, Brancati FL.

Ann Intern Med. 2007 Sep 18;147(6):386-99. Epub 2007 Jul 16. Review. Erratum in: Ann Intern Med. 2007 Dec 18;147(12):887.

PMID:
17638715
11.

Oral antihyperglycemic treatment options for type 2 diabetes mellitus.

Brietzke SA.

Med Clin North Am. 2015 Jan;99(1):87-106. doi: 10.1016/j.mcna.2014.08.012. Epub 2014 Oct 18. Review.

PMID:
25456645
12.
13.

After avandia: the use of antidiabetic drugs in patients with heart failure.

Khalaf KI, Taegtmeyer H.

Tex Heart Inst J. 2012;39(2):174-8. Review.

14.
15.

Safety and efficacy of rosiglitazone in the elderly diabetic patient.

Viljoen A, Sinclair A.

Vasc Health Risk Manag. 2009;5(1):389-95. Review.

16.

Risks and benefits of attaining HbA(1c) goals: examining the evidence.

Shubrook JH Jr.

J Am Osteopath Assoc. 2010 Jul;110(7 Suppl 7):eS7-12. Review. Erratum in: J Am Osteopath Assoc. 2010 Oct;110(10):572. Shubrook, Jay [corrected to Shubrook, Jay H Jr].

PMID:
20644204
17.

A risk-benefit assessment of metformin in type 2 diabetes mellitus.

Howlett HC, Bailey CJ.

Drug Saf. 1999 Jun;20(6):489-503. Review.

PMID:
10392666
18.

AHRQ's comparative effectiveness research on oral medications for type 2 diabetes: a summary of the key findings.

Bennett WL, Balfe LM, Faysal JM.

J Manag Care Pharm. 2012 Jan-Feb;18(1 Suppl A):1-22. Review.

19.

Treatment of type 2 diabetes: New clinical studies and effects of GLP-1 on macrovascular complications.

Lesven S, Gautier JF, Maréchaud R.

Ann Endocrinol (Paris). 2010 Dec;71(6):505-10. doi: 10.1016/j.ando.2010.09.001. Epub 2010 Oct 27. Review. Erratum in: Ann Endocrinol (Paris). 2011 Feb;72(1):13.

PMID:
21030006
20.

Advantages of extended-release metformin in patients with type 2 diabetes mellitus.

Jabbour S, Ziring B.

Postgrad Med. 2011 Jan;123(1):15-23. doi: 10.3810/pgm.2011.01.2241. Review.

PMID:
21293080
Items per page

Supplemental Content

Write to the Help Desk